Biosimilar development: Optimizing PK/PD studies
Parexel experts from regulatory, Early Phase Clinical Unit (EPCU) and translational and genomic medicine discuss the need to conduct comparative efficacy trials (CET) in the development of biosimilars. Although the international regulatory trend (led by FDA and MHRA) is to waive the CET, the Committee on Healthcare Medicinal Products (CHMP) in Europe currently still requires such trials.
The waiver of CETs will undoubtedly result in greater emphasis on the quality and pharmacokinetic (PK) data. Therefore, based on two decades of Parexel’s experts’ practical experience with biosimilars PK/PD studies, the following aspects are discussed in this whitepaper:
A. Justifying the waiver of CETs in the development of biosimilars
B. Considerations for the design of PK/PD biosimilar studies
C. Navigating the potential confounding factors in the conduct of PK/PD biosimilar studies
Related Insights
Article
Regulation pathway/strategy: Key considerations for foreign medical product registration in China
Jul 1, 2025
Whitepaper
Optimizing the Route to Regulatory Approval for a Novel Vaccine
Aug 18, 2023
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Webinar
How to navigate China’s regulatory environment
Feb 15, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Playbook
Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success
Mar 28, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Whitepaper
How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU
Jun 28, 2023
Related Insights
Article
Regulation pathway/strategy: Key considerations for foreign medical product registration in China
Jul 1, 2025
Whitepaper
Optimizing the Route to Regulatory Approval for a Novel Vaccine
Aug 18, 2023
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Webinar
How to navigate China’s regulatory environment
Feb 15, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Playbook
Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success
Mar 28, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Whitepaper
How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU
Jun 28, 2023